Acurx Pharmaceuticals posts presentation on ibezapolstat microbiome restoration potential in recurrent C. difficile infection - ACXP News | RalliesAcurx Pharmaceuticals posts presentation on ibezapolstat microbiome restoration potential in recurrent C. difficile infection
A
ACXP• Acurx publishes presentation on ibezapolstat research
- Acurx published research comparing ibezapolstat with fidaxomicin, vancomycin in patients with multiply recurrent C. difficile infection.
- Study found beneficial microbes remained present in these patients’ microbiomes, though at lower proportions.
- Reported higher vancomycin-resistant Enterococcus levels; ibezapolstat exposure in CDI patients was described as sufficient to kill VRE.
- Lab models showed VRE overgrowth with vancomycin; ibezapolstat, fidaxomicin outperformed in biofilms.
- Ibezapolstat was significantly more effective at C. difficile killing than vancomycin, fidaxomicin in biofilm experiments.
MDGL
•
